Ultragenyx Pharmaceutical Inc. Files 8-K
Ticker: RARE · Form: 8-K · Filed: Jul 9, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: UGNX
TL;DR
UGNX filed an 8-K, something happened, details TBD.
AI Summary
Ultragenyx Pharmaceutical Inc. filed an 8-K on July 9, 2025, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Ultragenyx Pharmaceutical Inc. that requires disclosure to investors, though the specifics are not yet detailed.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications detailed within the provided text.
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Registrant
- July 09, 2025 (date) — Filing date and earliest event reported
- 60 Leveroni Court, Novato, California 94949 (location) — Principal Executive Offices
FAQ
What specific event is Ultragenyx Pharmaceutical Inc. reporting in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.
When was this 8-K filing submitted to the SEC?
The filing was submitted on July 09, 2025.
What is the principal executive office address for Ultragenyx Pharmaceutical Inc.?
The principal executive offices are located at 60 Leveroni Court, Novato, California 94949.
What is the Commission File Number for Ultragenyx Pharmaceutical Inc.?
The Commission File Number is 001-36276.
Does this filing indicate any immediate financial impact or transaction details?
No, the provided text of the 8-K filing does not include specific financial amounts or details of any transactions.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 9, 2025 regarding Ultragenyx Pharmaceutical Inc. (RARE).